Please login to the form below

Not currently logged in
Email:
Password:

Aesica acquires R&D company R5

API manufacturer Aesica Pharmaceuticals has acquired fellow UK-based R5, a company specialising in research and development

Aesica Pharmaceuticals has acquired R&D company R5, which develops and manufactures new medicines and clinical trial materials.

This represents Aesica's third UK acquisition since 2006. The company, which manufactures active pharmaceutical ingredients (APIs) and was ranked 50th in Deloitte's Buyout Track 100, hopes that the new acquisition will complement its existing formulations capability and enable it to consolidate and enhance its portfolio of pharmaceutical and biotechnology clients significantly.

R5, which is based in Nottingham, will retain its current identity and brand, but it will become a subsidiary of Aesica, based in Newcastle. Key members of the Aesica team — Robert Hardy, CEO; John McConnell, HR director, and Paul Nicholson in corporate finance — will join the R5 board.

"R5 has a proven track record in delivering early phase formulation development and its reputation within the emerging biotechnology industry was of particular interest, as we begin to increase our portfolio of clients within this field," Robert Hardy said in a statement.

"We are hoping to harness the exceptional expertise and knowledge across the team at R5 to facilitate our continued expansion and to achieve our vision of becoming the leading supplier of active pharmaceutical ingredients and formulated products to the global pharmaceutical and biotechnology industries."

As one of the fastest growing companies in the UK, Aesica has increased turnover by 300 per cent over the course of the last five years since its formation in September 2004 and now has an annual turnover in the region of £100m. The company is currently undergoing significant expansion both in the UK and the US, having recently opened new offices in San Diego and New York, and has bolstered its resource from 140 to 700 employees.

29th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics